Cheyne Capital Management (Uk) LLP Biocryst Pharmaceuticals Inc Transaction History

Cheyne Capital Management (Uk) LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 08, 2019	SELL	$2.91 - $9.15 $145,500 - $457,500	-50,000 Closed	0 $0
Q4 2018 Feb 05, 2019	SELL	$6.51 - $9.6 $325,500 - $480,000	-50,000 Reduced 50.0%	50,000 $404,000
Q3 2018 Dec 21, 2018	SELL	$5.52 - $7.99 $552,000 - $799,000	-100,000 Reduced 50.0%	100,000 $763,000
Q3 2018 Nov 05, 2018	BUY	$5.52 - $7.99 $552,000 - $799,000	100,000 Added 100.0%	200,000 $1.53 Million
Q1 2018 May 10, 2018	BUY	$4.35 - $5.82 $434,999 - $582,000	100,000 New	100,000 $477,000

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.43B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Cheyne Capital Management (Uk) LLP, based on Form 13F filings with the SEC.

Stay updated on Cheyne Capital Management (Uk) LLP with notifications on news.